Zoetis heads into its August 5 earnings report with options traders growing more defensive, short sellers rebuilding positions, and Morgan Stanley trimming its target — all on the same day.
The sharpest new development is the Morgan Stanley action. Analyst Erin Wright lowered her price target from $115 to $99 today while maintaining an Overweight rating. That move is consistent with a broader pattern: since the May 7 earnings collapse — when ZTS fell 25.5% in a single session and lost 32% over the following week — the Street has been in steady retreat on targets. HSBC cut from $140 to $95 on July 6. Barclays moved from $136 to $85 on July 1. The consensus now clusters around $113.82, which implies roughly 51% upside from the current $75.35 price. That premium is hard to ignore, but it reflects where analysts thought the stock should trade before the May print rewrote the fundamental story. The direction of travel matters more than the absolute level: nearly every recent move has been a cut, and the Morgan Stanley action today confirms the trend has not stopped.
The bull case rests on Zoetis's pipeline depth, companion animal market leadership, and the secular growth of the human-animal bond. Bears flag the risk that the May quarter's weakness — whatever drove a 25% single-day drop — was not a one-off. The EPS momentum factor scores (42 on 30-day, 40 on 90-day) sit below the median, suggesting estimate revisions have been running negative. The PE multiple has compressed to around 10.5x trailing, down modestly over the past month, which may attract value-oriented holders but offers little reassurance about the growth trajectory. The dividend score ranks at the 100th percentile, a reminder that ZTS's income credentials are intact even as its growth premium erodes.
Short interest has risen 24% over the past month to 3.9% of free float — a meaningful build in absolute terms but not yet in extreme territory. The week-on-week move is roughly 6%, with most of that coming between July 14 and July 17. The lending market remains very loose: availability is running at over 2,300% relative to shares borrowed, meaning there are many multiples more shares available to lend than are currently out on loan. Cost to borrow has nearly doubled over the past week to 0.51%, but that's from a very low base and remains firmly in "easy borrow" territory. The short score of 36.2 has drifted slightly higher over the week but is not flashing an extreme reading. Short sellers are adding, but the borrow market is not under any stress.
Options positioning tells a more urgent story. The put/call ratio closed Tuesday at 0.628 — more than two standard deviations above its 20-day average of 0.49. That is the most elevated defensive positioning in options seen on this name in recent weeks, and the timing is deliberate: August 5 is now less than two weeks out. The last time ZTS reported, options-implied protection proved well-founded. Buyers of puts ahead of May 7 were vindicated by a 25% drop.
Three board-level directors — the Independent Chairman and two independent directors — bought shares in mid-May at prices between $75 and $78, right in the range where the stock trades today. Those purchases, totalling roughly $886,000 combined, were open-market buys at current levels rather than award grants. That cluster of insider buying at this price point is the clearest counter-signal to the bearish setup. Whether it reflects genuine conviction or simply directors defending their institution is the question the August 5 print will begin to answer.
What to watch: the degree to which August 5 results either validate the Street's relentless target-cutting or provide a floor — because at $75.35 with insider buyers at the same level and a consensus target still more than 50% higher, the spread between the pessimistic and optimistic reads on this stock is as wide as it has been all year.
See the live data behind this article on ORTEX.
Open ZTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
